Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

Patients who have planned lobar radioembolization (TheraSphere (TS)) and consent to this
study will have peripheral blood samples collected pre-TS, post-TS, 4 hours post-TS, 24 hours
post-TS, 3 days post-TS, 7 days post-TS and 30 days post-TS to analyze specific angiogenic,
inflammatory and immune profiles.

Inclusion Criteria:

- Must have the diagnosis of HCC (biopsy or imaging criteria)

- Must have planned lobar TheraSphere treatment

- Must be able to give consent

- Must have an ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 2

- Must have a life expectancy of ≥ 3 months

- Women must not be pregnant with an acceptable contraception in premenopausal women

- Must be > 4 weeks since prior radiation

- Must be > 2 weeks since liver surgery

- Must be ≥ 2 weeks post radiosensitizing chemotherapy or > 6 weeks since prior BCNU
(carmustine) or Mitomycin-C

Exclusion Criteria:

- Patients are excluded if they do not meet the inclusion criteria